Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey
Conclusion:
In a connected model of patient satisfaction, effectiveness, side effects, convenience and adherence, patients’ individual needs and concerns have to be addressed. Most differences were found with respect to side effects and convenience of treatment. Therefore, an improvement in these two domains seems to be the most promising proximate approach to elevate adherence levels. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - June 20, 2016 Category: Neurology Authors: Haase, R., Kullmann, J. S., Ziemssen, T. Tags: Original Research Source Type: research
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
Conclusion Compared with placebo, clear reductions in ARR with disease-modifying therapies were accompanied by more uncertain changes in disability progression. The magnitude of the reduction and the uncertainty associated with treatment effects varied between DMTs. While natalizumab and alemtuzumab demonstrated consistently high ranking across outcomes, with older interferon-beta and glatiramer acetate products ranking lowest, variation in disability progression definitions lead to variation in the relative ranking of treatments. Rigorously conducted comparative studies are required to fully evaluate the comparative treat...
Source: Multiple Sclerosis and Related Disorders - June 7, 2016 Category: Neurology Source Type: research
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors
Conclusion
BETACONNECT attributes and features were highly rated by patients, compared with both an ideal autoinjector and their current mechanical autoinjectors. These findings suggest that the use of BETACONNECT may increase patient satisfaction and potentially increase overall medication adherence.
Funding
Bayer HealthCare Pharmaceuticals. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 7, 2016 Category: Neurology Source Type: research
[Correspondence] Why use sex hormones in relapsing-remitting multiple sclerosis?
I read with interest Rhonda Voskuhl and colleagues' report1 of a phase 2 trial of the combination of estriol and glatiramer acetate for women with relapsing-remitting multiple sclerosis, and Annette Langer-Gould's Commentary2 on the Article. However, the authors did not seem to be aware of the immunomodulatory effect during pregnancy of interferon tau, which is produced by trophoblast cells in the human placenta.3 The structure and effects of this interferon are similar to those of interferon beta-1a (Rebif, Avonex) and interferon beta-1b (Betaseron, Biogen, Cambridge, MA, USA). (Source: Lancet Neurology)
Source: Lancet Neurology - June 7, 2016 Category: Neurology Authors: Richard Lechtenberg Tags: Correspondence Source Type: research
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain
Conclusion Early treatment with IFNβ-1b after a CIS vs. delayed treatment is efficient from a social perspective, but it may not be efficient from the perspective of the NHS which does not take non health-related costs into account. (Source: Neurologia)
Source: Neurologia - May 16, 2016 Category: Neurology Source Type: research
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
The objective of the study was to compare depression incidence in relapsing–remitting MS patients receiving interferon beta-1b (IFNB-1b) or glatiramer acetate (GA) in the BEYOND trial. 891/897 (99 %) of English, French, Spanish and Italian speakers among 2244 patients randomized (2:2:1) to receive either IFNB-1b 500 µg, 250 µg, or GA 20 mg QD for 2–3.5 years submitted Beck Depression Inventory Second Edition (BDI-II) scores at screening and serially thereafter, in which scores ≥14 indicated depression. Baseline BDI-II scores ≥14 were reported in 232/891 patients (26.3 %), with no meaningful difference among...
Source: Journal of Neurology - May 12, 2016 Category: Neurology Source Type: research
Cost-Utility Analysis of Intramuscular Interferon Beta-1b Versus Subcutaneous Interferon Beta-1b and Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in Colombia
To determine cost-utility of interferons intramuscular beta-1-a (IFNβ-1a-IM), subcutaneous beta-1-a (IFNβ-1a-SC), subcutaneous beta-1-b (IFNβ-1b-SC) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in Colombia. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: J Ordoñez, A Delgado Source Type: research
Health Economic Evaluation Of Interferon Beta 1b Versus 1a For Patients Diagnosed With Relapsing Remitting Multiple Sclerosis
The objective of this study is to conduct a health economic evaluation and compare the health care costs associated with patients diagnosed with relapsing remitting multiple sclerosis and taking Interferon beta 1b (Extavia) or Interferon beta 1a (Rebif) subcutaneously. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Greene, N Greene Source Type: research
Comparison Of Characteristics Of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis And Taking Subcutaneously Administered Disease Modifying Therapies: Interferon Beta 1b Versus 1a
The objective of this study is to assess and compare the characteristics of relapsing remitting multiple sclerosis (RRMS) patients taking Interferon beta 1b (Extavia) or Interferon beta 1a (Rebif) subcutaneously. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Greene, N Greene Source Type: research
Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy
Conclusions
Immunomodulatory IFN-β-1b treatment is a well-tolerated and safe treatment option, leading to effective virus clearance or reduction of the virus load in patients with chronic viral cardiomyopathy. Favourable clinical effects assess quality of life, NYHA functional class, and patient global assessment.
ClinicalTrials.gov identifier: NCT001185250 (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - April 24, 2016 Category: Cardiology Source Type: research
Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary
Conclusion
Persistence in this study was in the published range of observational MS studies. Furthermore, in male patients continuation of therapy might be positively influenced by use of a PDA, and both female and male patients might benefit from an integrated reminder function. In conclusion, electronic diaries reminding patients of upcoming injections can promote an improved adherence to MS therapy.
Trial registration
ClinicalTrials.gov identifier: NCT00902135.
Fundi...
Source: Advances in Therapy - April 17, 2016 Category: Drugs & Pharmacology Source Type: research
Interim Analysis of the Effectiveness of Second-Line Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients Treated with Prior First-Line Treatment, Other Than Natalizumab, in Spain: The Observational, Retrospective NEXT Study (P3.106)
CONCLUSIONS: Regardless of prior DMT, fingolimod significantly suppresses clinical disease activity and most of the patients have a stable and sustained EDSS after one year of treatment. The number of reported adverse events is consistent with previous findings from clinical trials. Long term therapy with fingolimod has a high treatment persistency.Disclosure: Dr. Meca Lallana has received research support for activities with commercial entities. Dr. Martinez Ginés has nothing to disclose. Dr. Mallada has nothing to disclose. Dr. Marzo has nothing to disclose. Dr. Marzo has nothing to disclose. Dr. Barrero has recei...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Meca, V., Martinez, M., Mallada, J. J., Marzo, E., Marzo, E., Barrero, F., Ricart, F. J., Garcia, E. Tags: MS and CNS Inflammatory Disease: Switching and Comparator Studies I Source Type: research
Antidepressant Use in Association with Multiple Sclerosis Disease Modifying Therapy (P2.180)
Conclusions: There is no correlation between depression and interferon treatment in the MS population. Depression rates are higher in older populations and females, also mirroring the Patten et. al. data. Antidepressant rate in patients with MS without DMTs was 32.2[percnt], which could exist for various reasons. EPM limitations include a lack of specific patient information, and rounding of patient cohorts to the nearest 10.Disclosure: Dr. Mirsky has nothing to disclose. Dr. Rae-Grant has nothing to disclose. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mirsky, M., Rae-Grant, A. Tags: MS and CNS Inflammatory Disease: MS Symptoms, Specific Symptoms Treatments, Co-morbidities and Cost Source Type: research
Predictors of Long-Term Interferon Discontinuation in Newly Diagnosed Relapsing Multiple Sclerosis (P6.174)
CONCLUSIONS. There are different factors associated with the risk of Interferon-β discontinuation, prescribed as first DMT for MS. Most of them are not modifiable, and are part of demographic features (i.e. gender), or of disease characteristics (i.e. relapses and disability status). However, the use of Interferon-β-1b is associated with a 50[percnt] increased risk of discontinuation, as compared to high-dose Interferon-β-1a, highlighting the importance of drug formulations in treatment persistence.Disclosure: Dr. Moccia has nothing to disclose. Dr. Palladino has nothing to disclose. Dr. Lanzillo has nothing...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Moccia, M., Palladino, R., Lanzillo, R., Brescia Morra, V. Tags: MS and CNS Inflammatory Disease: Switching and Comparator Studies II Source Type: research
Differences in Work Productivity Activity Impairment in MS Patients Initiated on Oral DMF versus Interferon Beta or Glatiramer Acetate in Europe and the US (P6.176)
Conclusion: Compared with ABCRE patients, patients on DMF had a significantly lower work productivity loss as measured by WPAI-MS.Disclosure: Dr. Iyer has received personal compensation for activities with Biogen as an employee. Dr. Jones has received personal compensation for activities with Aldelphi as an employee. Dr. Edwards has received personal compensation for activities with Biogen as an employee. Mr. Lee has received personal compensation for activities with Biogen as an employee. Dr. Pike has received personal compensation for activities with Adelphi Group as an employee. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Iyer, R., Jones, E., Edwards, M., Lee, A., Pike, J. Tags: MS and CNS Inflammatory Disease: Switching and Comparator Studies II Source Type: research
